High-density micropulse photocoagulation combined with intravitreal injection of ranibizumab for diabetic macular edema
10.13389/j.cnki.rao.2017.0070
- VernacularTitle:高密度微脉冲激光联合玻璃体内注射雷珠单抗治疗糖尿病性黄斑水肿
- Author:
Guangli SUN
;
Jing JIANG
;
Chenghu WANG
;
Shu ZHANG
;
Jin YAO
- Keywords:
diabetic macular edema;
ranibizumab;
high-density micropulse photo-coagulation
- From:
Recent Advances in Ophthalmology
2017;37(3):279-281
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effects of high-density micropulse photocoagulation (HD-SDM) combined with intravitreal injection of ranibizumab for diabetic macular edema (DME).Methods Thirty-one patients (31 eyes) with DME were randomly divided into two groups.Group A (15 eyes) received HD-SDM combined with intravitreal injection of ranibizumab.Group B (16 eyes) only received intravitreal injection of ranibizumab.The best corrected visual acuity (BCVA) and central macular thickness (CMT) of the two groups before and after treatment were analyzed,and the annual injection times of the two groups were compared.Results The average annual injection times was 3.67 ± 1.11 in group A,and 9.12 ±2.63 in group B.The difference was significant between the two groups (t =2.05,P ＜ 0.05).There were significant differences in CMT before and after treatment in both groups (all P ＜ 0.05).There was no significant difference in CMT between the two groups(t =1.19,P ＞ 0.05).There were significant differences in BCVA before and after treatment in both groups (all P ＜ 0.05),but there was no significant difference before and after treatment between the two groups(all P ＞ 0.05).Conclusion Both HD-SDM combined with intravitreal injection of ranibizumab and single intravitreal injection of ranlbizumab are effective for DME,but the combining treatment can remarkably decrease the annual injection times and had a good compliance of patients,is a good choice for DME patients.
